To order Bronchogen for laboratory research, investigators must evaluate structural sequence purity, functional mechanisms in pulmonary models, and price structures linked to rigorous analytical validation. PX1 Research provides high-purity, USA-manufactured Bronchogen verified by third-party HPLC and mass spectrometry to ensure reproducible experimental results across in vitro and preclinical assays.
To order Bronchogen for laboratory research, investigators must evaluate structural sequence purity, functional mechanisms in pulmonary models, and price structures linked to rigorous analytical validation. PX1 Research provides high-purity, USA-manufactured Bronchogen verified by third-party HPLC and mass spectrometry to ensure reproducible experimental results across in vitro and preclinical assays.
When evaluating options to order Bronchogen structural functional price metrics, principal investigators and laboratory buyers must balance chemical synthesis standards with analytical verification. Bronchogen is a short synthetic tetrapeptide (Ala-Asp-Glu-Leu) researched primarily for its interaction with bronchial epithelial tissue kinetics and gene transcription regulation. Acquiring research-grade material requires verifying structural identity via mass spectrometry, functional viability via low endotoxin thresholds, and unit pricing driven by verified high-performance liquid chromatography (HPLC) purity ratings exceeding 98%.
At PX1 Research, we provide institutional laboratories with fully validated research compounds supported by lot-specific documentation. Investigators browsing the PX1 Research product catalog can acquire high-purity materials optimized for rigorous in vitro and animal models, ensuring that pricing reflects true analytical quality rather than unverified commercial claims.
Bronchogen is classified as a short bioregulatory peptide consisting of four amino acid residues: L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu). With a molecular weight of approximately 446.45 g/mol, its short chain length enables distinct conformational flexibility and electrostatic binding kinetics compared to larger tertiary proteins. The peptide features two acidic side chains contributed by aspartic acid and glutamic acid, balanced by an N-terminal alanine and a C-terminal hydrophobic leucine residue.
In structural biology assays, this specific amino acid sequence demonstrates selective affinity for specific histone proteins and double-stranded DNA grooves. The primary chemical structure dictates how the molecule interacts with nuclear material in pulmonary epithelial cultures. When ordering peptides for structural modeling, verifying sequence accuracy via Electrospray Ionization Mass Spectrometry (ESI-MS) is critical, as minor deletions or substitutions significantly alter molecular binding kinetics.
Preclinical investigations into Bronchogen focus on its functional influence on respiratory tract tissues, specifically bronchial smooth muscle cells and ciliated epithelial populations. In vitro data indicate that short regulatory peptides can cross cellular and nuclear membranes without specialized receptor transporters, allowing direct interaction with promoter regions of specific genes.
In cell culture models of oxidative stress and inflammatory challenge, Bronchogen has been observed to modulate expression profiles of pro-inflammatory cytokines such as IL-6, TNF-alpha, and TGF-beta1. Preclinical studies suggest that this transcriptional modulation helps preserve epithelial barrier integrity, reduce extracellular matrix remodeling, and support surfactant-associated protein expression. Researchers studying pulmonary cellular senescence utilize the Bronchogen research vial to quantify changes in apoptosis markers and tissue-specific enzymatic activity.
Bronchogen belongs to a broader class of ultra-short peptide bioregulators originally conceptualized to target organ-specific gene expression. To understand its unique functional profile, researchers frequently compare Bronchogen with other short synthetic peptides operating under similar structural mechanisms.
While Bronchogen specifically targets pulmonary and bronchial tissue targets, compounds such as Vilon structural analysis (Lys-Glu) exhibit generalized immunomodulatory effects across splenocyte and thymocyte populations. Similarly, Epitalon mechanism study (Ala-Glu-Asp-Gly) focuses on neuroendocrine regulation and telomerase expression in pineal tissue models, and Thymogen preclinical review (Glu-Trp) is predominantly evaluated in T-cell differentiation assays. Comparing these molecules in standardized cell cultures allows investigators to isolate tissue-specific transcriptional responses from non-specific peptide signaling.
The analytical evaluation of Bronchogen relies on tandem analytical techniques to confirm both structural identity and chemical purity. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is utilized to measure optical purity and detect trace peptide impurities resulting from incomplete coupling steps during solid-phase peptide synthesis (SPPS). A standard research specification requires an RP-HPLC purity profile of 98.0% or higher.
Mass spectrometry complements HPLC by measuring the exact mass-to-charge ratio (m/z) of the synthesized tetrapeptide. ESI-MS spectrum analysis confirms the presence of the 446.45 Da molecular ion peak without secondary peak clusters indicating truncated sequences or adduct formation. When preparing to order material, researchers should review complete spectral data available in our PX1 Research repository to confirm lot-to-lot consistency.
When analyzing the phrase 'order bronchogen structural functional price', researchers often seek to understand why pricing varies across scientific reagent vendors. The total cost of high-grade research peptides is primarily governed by four quality factors:
1. Synthesis Scale & Method: High-efficiency solid-phase synthesis protocols designed for short peptides require specialized protected amino acids and high-purity reagents. 2. Purification Complexity: Achieving >98% purity requires iterative preparative HPLC runs, which reduce overall yield but guarantee chemical isolation. 3. Quality Control Assays: Third-party testing using ISO 17025 accredited facilities adds essential validation overhead, including independent ESI-MS, RP-HPLC, and endotoxin testing. 4. Storage and Supply Chain Stability: Maintaining cold-chain storage and inert gas flushing prevents peptide degradation during transit.
Laboratories managing high-throughput assays or multi-phase rodent trials can utilize the PX1 bulk lab purchasing portal to optimize cost-per-milligram metrics while maintaining analytical quality standards.
To maintain structural stability and functional activity, Bronchogen must be handled according to strict physical chemistry protocols. The lyophilized powder is highly hygroscopic and should be stored at -20°C in a desiccated environment prior to reconstitution.
Reconstitution should be performed using sterile laboratory-grade solvents such as Bacteriostatic Water, Sterile Water for Injection, or Phosphate-Buffered Saline (PBS, pH 7.4), depending on the requirements of the downstream assay. Once reconstituted, the peptide solution should be aliquoted into single-use polypropylene tubes to avoid repeated freeze-thaw cycles, which can induce peptide bond hydrolysis or aggregation. Reconstituted aliquots remain stable at 2°C to 8°C for short-term experimentation (up to 7 days) or at -80°C for extended storage.
Endotoxin contamination represents a major confounding variable in cell culture and animal research. Lipopolysaccharides (LPS) derived from Gram-negative bacterial outer membranes can trigger robust inflammatory responses in macrophages and epithelial cells, falsifying the observed functional impact of the peptide being studied.
PX1 Research enforces strict endotoxin limits (<0.05 EU/mg) verified via chromogenic Limulus Amebocyte Lysate (LAL) testing. Ensuring low endotoxin levels guarantees that cellular changes observed in pulmonary models are directly attributable to the structural activity of Bronchogen rather than artifactual bacterial contamination. Detailed documentation regarding regulatory compliance and testing protocols is detailed in our overview of Khavinson peptide research hub.
Sourcing research peptides requires vendor reliability, rapid fulfillment, and complete batch traceability. PX1 Research synthesizes and packages all compounds within GMP-compliant, USA-based facilities. Orders originate from our centralized distribution hubs in California and Arizona, allowing for immediate processing and rapid domestic delivery.
Every shipment includes a lot-specific Certificate of Analysis (COA) detailing the verified mass spectrum, HPLC purity trace, and endotoxin assessment. By establishing transparent quality verification and dependable logistics, PX1 Research supports academic, biopharmaceutical, and contract research organizations in maintaining seamless experimental timelines.
What is the primary structural sequence of Bronchogen?
Bronchogen is a synthetic tetrapeptide consisting of the amino acid sequence L-alanyl-L-alpha-aspartyl-L-alpha-glutamyl-L-leucine (Ala-Asp-Glu-Leu), with a molecular weight of approximately 446.45 g/mol.
How is the functional purity of Bronchogen verified?
Purity is verified through Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure chemical isolation above 98.0%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm molecular mass and sequence identity.
What factors influence the price when ordering Bronchogen for research?
Pricing is determined by the purity threshold (>98% vs lower technical grades), synthesis yield, third-party analytical testing (HPLC/MS), endotoxin assay verification, and volume scale (analytical vials vs. bulk lab quantities).
What solvent should be used to reconstitute Bronchogen for in vitro assays?
Common laboratory solvents include sterile Phosphate-Buffered Saline (PBS, pH 7.4), sterile laboratory water, or bacteriostatic water, chosen based on the compatibility of the specific biological assay.
Why is endotoxin testing critical when purchasing Bronchogen?
Bacterial endotoxins can stimulate cellular immune responses in vitro, leading to false-positive inflammatory data. PX1 Research enforces endotoxin thresholds below 0.05 EU/mg to eliminate research artifacts.
How should reconstituted Bronchogen be stored?
Reconstituted solutions should be divided into single-use aliquots and stored at -20°C or -80°C to prevent degradation from repeated freeze-thaw cycles. Short-term storage at 2–8°C is acceptable for up to 7 days.
Is Bronchogen intended for human consumption or clinical use?
No. Bronchogen supplied by PX1 Research is strictly designated for in vitro, cellular, and preclinical laboratory research use only. It is not for human or veterinary medical, therapeutic, or diagnostic application.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based facilities and dispatched directly from distribution centers in California and Arizona with same-day shipping on standard business days.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.